Thymosin Beta-4 (TB-500): Biology, Mechanisms and What the Research Shows

Thymosin beta-4 (Tβ4) is a 43-amino-acid peptide that sits at the centre of how cells rebuild themselves. It is the main intracellular actin-sequestering peptide in mammals, which makes it a master switch for cell shape, cell movement and tissue remodelling. Researchers study it because that one job connects to almost every stage of repair: migration, angiogenesis, inflammation control and cell survival.

This article covers what thymosin beta-4 is, how it differs from TB-500, what the preclinical literature actually reports, and how research material should be verified before a study begins.

Key Takeaways

• Thymosin beta-4 is a 43-amino-acid, ~5 kDa peptide, the most abundant member of the β-thymosin family, and is found in nearly every tissue except red blood cells.
• Its defining function is sequestering monomeric G-actin, which regulates cytoskeletal remodelling and directed cell migration.
• TB-500 is not the same molecule — it is a short synthetic fragment (LKKTETQ) of the actin-binding region.
• Published work spans corneal, dermal, cardiac, neural, hepatic and sepsis models, mostly preclinical or early-phase.
• Several bioactive fragments of Tβ4 carry narrower, more specific activity than the full-length peptide.
• Thymosin beta-4 is not an approved drug and is supplied strictly for laboratory research.

What Is Thymosin Beta-4?

Thymosin beta-4 is encoded by the TMSB4X gene and is highly conserved across species. At 43 amino acids and a molecular weight of roughly 4,963 g/mol, it is small, acidic and structurally flexible. Expression rises after tissue injury, which is one of the reasons it has been described in the literature as a repair peptide rather than a hormone.¹

Its best-characterised role is binding monomeric (G)-actin to hold a dynamic reserve of monomers available for polymerisation into filamentous (F)-actin. By buffering that pool — and by forming ternary complexes with partners such as profilin — Tβ4 governs the cytoskeletal remodelling behind chemotaxis, phagocytosis, cytokinesis and directed cell migration.²,³

Is TB-500 the Same Thing as Thymosin Beta-4?

No. The two names are used interchangeably in a lot of online material, and that is a mistake worth correcting before designing a study.

TB-500 is a synthetic fragment derived from thymosin beta-4. Its sequence is LKKTETQ, part of the actin-binding motif, with a molecular weight of about 889 g/mol. Full-length thymosin beta-4 carries the same motif plus the rest of the 43-residue chain, including an N-terminal domain associated with additional activity beyond actin handling.⁴

A third fragment is worth knowing about. Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is released from the N-terminus of thymosin beta-4 by prolyl oligopeptidase, not from TB-500, and has been studied separately for immune-regulating and pro-angiogenic activity.⁵

Because the naming is used loosely across suppliers and papers, the amino acid sequence — not the trade name — is the only reliable way to confirm which molecule is in front of you.

How Does Thymosin Beta-4 Work?

Actin Regulation and Cell Motility

Actin filaments are continually assembled and disassembled to support cell structure and movement. Tβ4 binds G-actin and buffers the monomer pool; controlled release of those monomers drives polymerisation, reshapes the cytoskeleton and enables directed migration. In rodent studies, raised Tβ4 activity coincides with wound healing, and exogenous administration has been reported to accelerate post-injury recovery.²,³

Angiogenesis and Matrix Remodelling

Repair depends on rapid revascularisation. Tβ4 promotes endothelial adhesion and migration and upregulates matrix metalloproteinases during wound repair, supporting new vessel formation and extracellular-matrix turnover at injury sites. Malinda and colleagues reported directional migration of human umbilical vein endothelial cells in response to Tβ4, and Philp and colleagues localised the pro-angiogenic effect to the actin-binding site itself.⁶,⁷

Inflammation Control

Tβ4 has been reported to down-regulate pro-inflammatory chemokines and cytokines — for example TNF-α-induced IL-8 in gingival fibroblast models — and to suppress corneal NF-κB signalling after injury. In the literature this is framed as curtailing the chronic inflammation that impairs healing and drives fibrosis.⁸

Cytoprotection and Cell Survival

By limiting apoptosis, oxidative injury and excitotoxic damage such as glutamate neurotoxicity, Tβ4 preserves cell viability under stress. Reduced myofibroblast-driven scarring and support for stem/progenitor cell maturation are also reported.¹

Platelet-Associated Release

Tβ4 is released alongside factor X from platelets and binds G-actin at injury sites, which aligns its availability with the earliest phase of tissue repair.¹

What Do the Animal Studies Show?

Ocular Surface and Cornea

In animal models, Tβ4 eye formulations accelerate re-epithelialisation and have outperformed saline and certain comparators. Sosne and colleagues reported promoted corneal wound healing and decreased inflammation following alkali injury.⁸ Phase 2 work has reported improvements in signs and symptoms of moderate-to-severe dry eye with favourable tolerability. Investigational settings include chemical burns, recurrent erosions, neurotrophic keratitis and post-refractive recovery.

Cardiac Ischaemia

Bock-Marquette and colleagues reported that Tβ4 activates integrin-linked kinase and promotes cardiac cell migration, survival and repair, and Smart and colleagues reported mobilisation of adult epicardial progenitors and neovascularisation.⁹,¹⁰ In a murine myocardial infarction model, treatment was associated with capillary formation, limited cardiomyocyte death and supported myocardial regeneration.

Neural Injury

Morris and colleagues reported improved functional neurological outcome in a rat embolic stroke model, and Xiong and colleagues reported improved neurological outcome and reduced neurovascular damage after traumatic brain injury in rats.¹¹,¹² Reported mechanisms include oligodendrocyte activation and support for neurovascular unit integrity, with greater vessel density and neural outgrowth in peri-lesional regions. Suh and colleagues additionally reported upregulated autophagy and improved cognitive measures in neurodegenerative models.¹³

Soft Tissue and Dermal Repair

Kleinman and Sosne summarised dermal healing activity, including reduced scarring and improved collagen deposition in preclinical wound models.¹⁴ Research settings extend to tendon, ligament and muscle injury and to pressure and venous ulcer models.

Liver and Immune Models

Serum Tβ4 has been reported to correlate inversely with inflammatory and fibrotic burden in chronic hepatitis B with NAFLD, with proposed suppression of TLR-driven inflammation along the gut–liver axis.¹⁵ Separate work has examined Tβ4 regulation of actin in sepsis.¹⁶

What Are the Thymosin Beta-4 Fragments?

Beyond the full-length peptide, several bioactive fragments have been characterised. Each retains a slice of Tβ4 biology, which is what makes them useful for narrowing an experimental question.

Wang and colleagues reported that Tβ4 reversed phenotypic polarisation of glial cells and cognitive impairment through negative regulation of the NF-κB signalling axis in APP/PS1 mice, which is one of the clearer demonstrations of fragment-relevant anti-inflammatory activity in the central nervous system.¹⁷

How Should Research Material Be Verified and Stored?

The integrity of any study using this peptide depends on the material itself. Because research compounds are not evaluated by the FDA for quality, purity varies between suppliers.

Verify identity and purity. Ask for third-party analytical testing in the form of a Certificate of Analysis tied to the specific lot. The document should confirm identity, state purity, and record the batch or lot number so results can be traced back to the material used.

Confirm the sequence, not the label. Thymosin beta-4 and TB-500 are different molecules. The COA should make clear which one the vial contains.

Store correctly. Lyophilised powder is the most stable form and should be kept cool, dry and out of direct light; refrigeration is standard for longer storage. Once reconstituted, stability falls sharply, so reconstituted material should stay refrigerated and be used within a defined window.

Handle cleanly. Reconstitution and aliquoting should happen in a clean environment to avoid contamination that would confound results.

What Is Still Unknown?

Most of the published evidence is preclinical. Controlled human trials establishing efficacy, dose, formulation and safety are still limited, and the ophthalmic programmes are the furthest along rather than representative of the field as a whole.

Open questions include pharmacokinetics and clearance, optimal timing relative to injury, whether fragment-specific activity holds up outside narrow models, and whether findings in rodents translate to human biology at all. Regulatory classification should not be read as evidence of safety or effectiveness in either direction.

Frequently Asked Questions

Is Thymosin Beta-4 Naturally Occurring?

Yes. Thymosin beta-4 is an endogenous peptide expressed in nearly all tissues except red blood cells, and its expression rises after injury. The material used in laboratory work is synthesised rather than extracted.

Why Do Suppliers Use “TB-500” and “Thymosin Beta-4” Interchangeably?

Largely convention. TB-500 became shorthand for the whole category even though it names a 7-residue fragment. Checking the sequence on the Certificate of Analysis is the only way to be certain which molecule a vial contains.

What Is Ac-SDKP?

Ac-SDKP is a four-residue fragment released from the N-terminus of thymosin beta-4 by prolyl oligopeptidase. It is studied separately for immune-regulating and pro-angiogenic activity and is not produced from TB-500.

What Is Thymosin Beta-4 Used For In Research?

Published work uses it in models of corneal and dermal wound healing, cardiac ischaemia, stroke and traumatic brain injury, soft-tissue repair, hepatic inflammation and sepsis. All of these are laboratory and preclinical contexts.

Is Thymosin Beta-4 Approved For Human Use?

No. It is not an approved drug, not an approved dietary supplement and not an approved clinical therapy. It is supplied for in-vitro and preclinical research only.
Disclaimer: Licensed Peptides products are supplied strictly for laboratory research purposes only. They are not intended for human consumption, clinical use, therapeutic application, diagnosis, treatment, cure, or prevention of any disease. This article is provided for educational and scientific discussion purposes only. All references to biological activity relate exclusively to laboratory, in vitro, and preclinical research.

References

1. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multifunctional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. doi:10.1517/14712598.2012.634793
2. Sanders MC, Goldstein AL, Wang YL. Thymosin β4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci USA. 1992;89(10):4678–4682. doi:10.1073/pnas.89.10.4678
3. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205–220. doi:10.1016/S1357-2725(00)00087-X
4. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. doi:10.1016/j.molmed.2005.07.004
5. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved in release of N-acetyl-seryl-aspartyl-lysyl-proline from thymosin-β4 in vivo. J Pharmacol Exp Ther. 2004;308(2):614–619. doi:10.1124/jpet.103.058453
6. Malinda KM, Goldstein AL, Kleinman HK. Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474–481. doi:10.1096/fasebj.11.6.9194528
7. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17(14):2103–2105. doi:10.1096/fj.03-0121fje
8. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin β4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293–299. doi:10.1006/exer.2001.1125
9. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472. doi:10.1038/nature03000
10. Smart N, Risebro CA, Melville AAD, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182. doi:10.1038/nature05383
11. Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674–682. doi:10.1016/j.neuroscience.2010.05.017
12. Xiong Y, Mahmood A, Meng Y, et al. Treatment of traumatic brain injury with thymosin β4 in rats. J Neurosurg. 2011;114(1):102–115. doi:10.3171/2010.4.JNS10118. PMID:20486893; PMCID:PMC2962722.
13. Suh H, Consentino D, Singh P, et al. Thymosin β4 upregulates autophagy and improves cognitive function in models of neurodegenerative disease. Brain Res. 2018;1681:1–12.
14. Kleinman HK, Sosne G. Thymosin β4 promotes dermal healing. Vitam Horm. 2016;102:251–275. doi:10.1016/bs.vh.2016.04.005
15. Jiang Y, Han T, Zhang Z, et al. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Dis Transl Med. 2017;3(3):165–168.
16. Belsky JB, Rivers EP, Filbin MR, et al. Thymosin beta 4 regulation of actin in sepsis. Expert Opin Biol Ther. 2018;18(sup1):193–197. doi:10.1080/14712598.2018.1448381
17. Wang M, Feng LR, Li ZL, et al. Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF-κB signaling axis in APP/PS1 mice. J Neuroinflammation. 2021;18(1):146. doi:10.1186/s12974-021-02166-3
18. Xing Y, Ye Y, Zuo H, Li Y. Progress on the function and application of thymosin β4. Front Endocrinol (Lausanne). 2021;12:767785. doi:10.3389/fendo.2021.767785. PMID:34992578; PMCID:PMC8724243.